文献速递淋巴瘤造血干细胞移植与细胞治疗

肠道微生物组与代谢物作为复发/难治性弥漫大B细胞淋巴瘤CAR-T疗效与毒性生物标志物的探索性研究

Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

本研究分析复发/难治性弥漫大B细胞淋巴瘤患者CAR-T治疗前(47份)及输注后1个月(32份)的粪便与血清样本,采用全基因组测序宏基因组学。结果提示应答者拟杆菌属脆弱种水平较高且肌苷合成通路富集,血清肌苷升高与无进展生存改善存在探索性关联;特定微生物分类群及血清脂肪酸谱与CAR-T相关不良事件相关。

要点

  • 复发/难治性DLBCL患者存在肠道菌群失调,表现为变形菌门和肠杆菌科增加。
  • 应答者拟杆菌属脆弱种较高,非应答者普拉梭菌较高,应答者肌苷合成通路富集。
  • 血清肌苷升高与无进展生存改善呈探索性关联;无不良事件者乙酸和丁酸较高,有不良事件者异戊酸升高。

核心结论

  • 肠道微生物组特征尤其是拟杆菌属脆弱种和肌苷代谢可能作为CAR-T治疗结局与毒性的候选生物标志物。
  • 由于分析为探索性且队列规模有限,结果需谨慎解读,尚需更大规模前瞻性研究验证。

研究设计与样本

  • 研究分析复发/难治性弥漫大B细胞淋巴瘤患者的粪便和血清样本,采血/单采时47份、输注后1个月32份。
  • 采用全基因组测序宏基因组学分析肠道微生物组,并与健康对照和新诊断DLBCL比较。

主要发现

  • 与健康对照和新诊断DLBCL相比,复发/难治性DLBCL显示显著肠道菌群失调,变形菌门和肠杆菌科增加。
  • 应答者拟杆菌属脆弱种水平较高,非应答者普拉梭菌水平较高。
  • 功能宏基因组分析提示应答者肌苷生物合成通路富集,血清肌苷升高与无进展生存改善呈探索性关联。
  • 特定微生物分类群和血清脂肪酸谱与CAR-T相关不良事件相关,无不良事件者乙酸和丁酸较高,有不良事件者异戊酸升高。

临床怎么用

  • 目前尚不能将肠道微生物组或代谢物指标常规用于CAR-T疗效或毒性预测,仅作为探索性候选标志物。
  • 需在更大规模前瞻性研究中验证拟杆菌属脆弱种、肌苷代谢及脂肪酸谱的预测价值。

局限性

  • 分析为探索性,队列规模有限,结果需谨慎解读。
  • 需要更大规模前瞻性研究验证观察结果并评估基于微生物组的策略优化CAR-T治疗的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL), but challenges such as posttreatment failure and immune-related adverse events (AEs) persist. This study explores the gut microbiome as a predictive biomarker for CAR T-cell therapy outcomes and toxicity. Stool and serum samples from patients with R/R-DLBCL were analyzed at apheresis (47 samples) and 1 month after infusion (32 samples) using whole-genome sequencing metagenomics. When compared with healthy controls and newly-diagnosed DLBCL, R/R-DLBCL showed significant gut dysbiosis, characterized by increased Proteobacteria and Enterobacteriaceae. Responders had higher levels of Bacteroides fragilis, whereas nonresponders exhibited higher levels of Faecalibacterium prausnitzii. Functional metagenomic analysis suggested enrichment of inosine biosynthesis pathways in responders, and elevated serum inosine demonstrated an exploratory association with improved progression-free survival. Distinct microbial taxa and serum fatty acid profiles were also linked to CAR T-cell-related AEs, with higher acetate and butyrate levels in patients without AEs and increased isovalerate in those with AEs. These findings indicate that gut microbiome features-particularly Bacteroides fragilis and inosine metabolism-may serve as candidate biomarkers for CAR T-cell therapy outcomes and toxicity. However, given the exploratory nature of these analyses and the limited cohort size, results should be interpreted cautiously. Larger, prospective studies will be required to validate these observations and to assess the potential of microbiome-based strategies to optimize CAR T-cell therapy in R/R-DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yoon SE, Kang W, Cho J, et al. Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2026. PMID: 41364878. doi:10.1182/bloodadvances.2025016858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。